(S)-N-Cbz-aspartic acid semialdehyde | 60655-04-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-N-Cbz-aspartic acid semialdehyde
• 英文别名: N-Benzyloxycarbonyl-L-asparaginsaeure-β-semialdehyd；N-Benzyloxycarbonyl-L-asparagin-β-halbaldehyd；(2S)-4-oxo-2-(phenylmethoxycarbonylamino)butanoic acid
• CAS: 60655-04-1
• 化学式: C₁₂H₁₃NO₅
• 分子量: 251.239
• InChiKey: XQXNNZHICLIJIQ-JTQLQIEISA-N

物化性质

• 沸点：
  471.9±45.0 °C(Predicted)
• 密度：
  1.302±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-N-Cbz-aspartic acid semialdehyde 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 生成 (2S)-2-氨基-4-氧代丁酸
  参考文献：
  名称：

  778. Synthesis ofL-aspartic β-semialdehyde

  摘要：

  DOI：

  10.1039/jr9620003963
• 作为产物：
  描述：

  N-CBZ--L-烯丙基甘氨酸 生成 (S)-N-Cbz-aspartic acid semialdehyde
  参考文献：
  名称：

  778. Synthesis ofL-aspartic β-semialdehyde

  摘要：

  DOI：

  10.1039/jr9620003963

文献信息

• ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180169256A1

  公开（公告）日：2018-06-21

  The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.

  这项发明涉及新型结合物-前药偶联物（APDCs），其中结合物与动力蛋白纺锤体抑制剂的非活性前体化合物偶联，以及抗体药物偶联物ADCs以及制备这些APDCs和ADCs的方法。
• ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20200138970A1

  公开（公告）日：2020-05-07

  The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型结合剂药物偶联物（ADCs），这些ADCs的活性代谢物，制备这些ADCs的过程，将这些ADCs用于治疗和/或预防疾病，以及将这些ADCs用于制备治疗和/或预防疾病的药物，特别是高增殖和/或血管生成异常等疾病，例如癌症等。这种治疗可以作为单独治疗，也可以与其他药物或其他治疗措施结合使用。
• PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20190077752A1

  公开（公告）日：2019-03-14

  The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are masked with legumain-cleavable groups and hence release the drug, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers.

  该发明涉及通式(Ia)的新型前药或结合物，其中细胞毒性药物，例如动力蛋白抑制剂，被腿蛋白酶可切割基团掩蔽，从而释放药物，并且涉及使用这些前药或结合物用于治疗和/或预防疾病，以及使用这些前药或结合物用于生产用于治疗和/或预防疾病的药物，特别是治疗和/或预防高增殖和/或血管生成异常的疾病，例如癌症。
• AMINO ACID COMPOUNDS AND METHODS OF USE
  申请人：Pliant Therapeutics, Inc.

  公开号：US20190276449A1

  公开（公告）日：2019-09-12

  The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R 1 , R 2 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  该发明涉及以下化合物的公式(A)和公式(I)：或其盐，其中R1、R2、R10、R11、R12、R13、R14、R15、R16、q和p如本文所述。公式(A)、公式(I)的化合物及其药物组合物是αvβ6整合素抑制剂，可用于治疗纤维化疾病，如特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• [EN] DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS<br/>[FR] FORMES POSOLOGIQUES ET SCHÉMAS DE TRAITEMENT POUR DES COMPOSÉS D'ACIDES AMINÉS
  申请人：PLIANT THERAPEUTICS INC

  公开号：WO2020210404A1

  公开（公告）日：2020-10-15

  The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ανβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP),

  该发明涉及用于每日给药的化合物(A)和化合物(I)的剂型：或其盐，其中R1、R2、R10、R11、R12、R13、R14、R15、R16、q和p如本文所述。化合物(A)、化合物(I)及其药物组成物是ανβ6整合素抑制剂，可用于治疗纤维化疾病，如特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。